Jerusalem/Needham (PRWEB) February 6, 2011
Oridion (SIX Swiss Exchange: ORIDN), creator of the Smart Capnography™ family of algorithm-based solutions, today announced the presentation of eight abstracts addressing the use of capnography monitoring in multiple clinical applications at the Society for Technology in Anesthesia (STA) annual conference in January.
Leading anesthesiologists and researchers, including several representatives from Oridion, were invited by STA to present clinical findings addressing capnography as a measure of adequacy of ventilation in multiple applications, including procedural sedation, obstructive sleep apnea patients, veterinary medicine, and the use of Integrated Pulmonary Index™ (IPI™) monitoring during pediatric endoscopies.
Going far beyond standard measures of respiratory rate, capnography provides continuous monitoring of the patient’s quality of ventilation by measuring the exhaled carbon dioxide and an instantaneous indication of changes in breathing through breath waveforms.
The STA annual meeting and conference was held January 12 – 15 in Las Vegas, Nevada, and featured a special session on “The Art, Science and Future of Non-Invasive Monitoring.”
Among the abstracts presented was “Capnography Improves Detection of Respiratory Events During Procedural Sedation,” a meta-analysis by Jonathan Waugh, PhD, RRT, RPFT, CTTS. This analysis revealed that during procedural sedation (PSA), cases of respiratory depression were 17.6 times more likely to be detected if monitored by capnography, versus cases not monitored by capnography. The abstract noted: “This analysis quantitatively supports the presumption of clinicians administering PSA that etCO2 monitoring is more effective than traditional monitoring modalities for detecting respiratory depression.”
In another abstract presented at STA, Greg Spratt, BS, RRT, CPFT, surveyed experienced users of capnography to compare capnography alarm settings commonly used between multiple care environments. In “Comparing Capnography Alarm Limits Used in Differing Care Environments,” the survey concluded that alarm limit requirements may vary significantly from one environment to the next based on patient needs, and each institution and ordering physician should adjust alarm limits based on the population being served and specific patient needs.
Selected abstracts presented at the STA conference will be published in future issues of Anesthesia & Analgesia.
Oridion also contributed to 32 manuscripts and abstracts published in 2010, increasing recognition of capnography as an accepted standard of care in multiple clinical settings, including procedural sedation, emergency medicine, respiratory care, critical care, post-operative patients (including bariatric surgical patients), sleep and pulmonary rehabilitation, pediatrics, and veterinary medicine.
Topics included “Keeping Patients Safe During Intra-hospital Transport,” “Preventing Unnecessary Deaths with Capnography”, “End-tidal Carbon Dioxide in Obstructive Sleep Apnea Patients,” “Capnography as a Survival Predictor in Cardiopulmonary Resuscitation,” “Capnography Is Superior to Pulse Oximetry for the Detection of Respiratory Depression During Colonoscopy,” and “Integrated Pulmonary Index™ Stability in Healthy Adults Under Changing Conditions.”
The articles and abstracts were published in a spectrum of clinical publications and peer-reviewed journals, including International Journal of Pediatrics, Respiratory Care, RT, American Journal of Otolaryngology, Resuscitation, SLEEP Journal of Sleep and Sleep Disorders Research, Critical Care Nurse and the Anesthesia Patient Safety Foundation Newsletter.
For further Oridion information please contact:
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
phone +972 2 589 9159
address Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in Israel and the United States.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient’s breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients’ ventilation may be compromised and at risk.
Certain statements made herein that are not historical are forward-looking. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology. The Company does not assure any obligation to update the forward looking information contained in this press release.
# # #